NeuroDex research library
Alzheimer’s disease: blood biomarker library
Plasma p-Tau217, Aβ42/40, GFAP and NfL have changed how Alzheimer’s pathology is detected. Drug programs still need to know more: which patients carry co-pathology, whether a drug changes neuronal biology, and how to pick a marker for each decision. These articles cover diagnosis, trial design and mechanism-of-action readouts from blood.
Start here
What Is a Blood Test for Alzheimer’s? A Complete 2026 GuideDiscover the essentials of diagnosing Alzheimer’s disease with a Blood Test for Alzheimer’s in our comprehensive 2026 guide.Alzheimer’s DiseaseAlzheimer’s disease, a progressive neurological disorder, has become an increasingly prevalent .Tau and pTau Biomarkers in Alzheimer’s DiseaseDiscover how Tau and pTau biomarkers indicate Alzheimer’s disease and their significance in neurological disorders.10 Kinds of DementiaDiscover the 10 Kinds of Dementia, their symptoms, and how they impact individuals and families in this informative guide. Kinds of Dementia.
Biomarkers in drug development
Biomarker Discovery for Alzheimer’s Drug Programs: What Blood-Based Platforms Can AddBiomarker Discovery for Alzheimer’s Drug Programs: see how blood-based CNS biomarkers track drug mechanism of action between PET and CSF trial visits.Biomarker Selection in Alzheimer’s and Prodromal AD CohortsAlzheimer’s blood biomarker clinical development fails at cohort selection, not sensitivity. How to match marker class to each decision gate in…Closing the Diagnostic Gap in Alzheimer’s: How Neuron-Derived Biomarkers Are Changing What’s MeasurableAlzheimer’s blood biomarkers detect pathology well, but peripheral plasma noise still blocks precise stratification. Here’s what actually closes that…What should you require from an Alzheimer’s tau biomarker testing partner?Alzheimer’s tau biomarker testing partners differ on provenance, precision and pre-analytical control — not sensitivity. Nine criteria for sponsor…Plasma p-Tau Specificity in ALS and Alzheimer’s TrialsPlasma p-tau217 rises in ALS as well as Alzheimer’s disease. What peripheral tau means for plasma p-tau specificity, patient selection and trial…LATE and Mixed Pathology: Separating Copathology Signals in BloodCan LATE be detected in blood? Plasma p-tau, NfL and GFAP cannot attribute signal to TDP-43. Neuron-derived EVs restore the provenance mixed pathology…
Assays
NeuroDex research
Field news
China Approves Leqembi® for Alzheimer’s Treatment: A New Hope in the Fight Against Cognitive DeclineChina Approves Leqembi.In a significant medical advancement, China has joined the United States and Japan in approving Leqembi® AL drug.Donanemab Shows Promising Results in Slowing Cognitive Decline in Alzheimer’s DiseaseEli Lilly recently presented the full results from their Phase 3 TRAILBLAZER-ALZ 2 study at the Alzheimer’sRoche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-makingRoche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment.FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, LeqembiFDA Advisory commitee supports Biogen and Eisai’s Alzheimer’s drug. The committee’s unanimous 6-0 vote concluded that Leqembi.

